Zhao X - Search Results

1

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.

Hu Z, Sun S, Zhao X, Yu H, Wu X, Wang J, Chang J, Wang H. Hu Z, et al. Among authors: zhao x. Oncologist. 2022 Apr 5;27(4):253-e312. doi: 10.1093/oncolo/oyab078. Oncologist. 2022. PMID: 35380726 Free PMC article. Clinical Trial.

2

Biweekly docetaxel-containing chemotherapy may be the optimal schedule.

Yang X, Cai Y, Zhao X, Wang Z, Hong X, Shen Z, Ou Z, Li J, Hu X. Yang X, et al. Among authors: zhao x. Anticancer Drugs. 2008 Apr;19(4):421-6. doi: 10.1097/CAD.0b013e3282f7f52e. Anticancer Drugs. 2008. PMID: 18454052 Clinical Trial.

3

The p21 Ser31Arg polymorphism and breast cancer risk: a meta-analysis involving 51,236 subjects.

Qiu LX, Zhang J, Zhu XD, Zheng CL, Sun S, Wang ZH, Zhao XM, Wang JL, Wang LP, Yu H, Xue K, Hu XC. Qiu LX, et al. Breast Cancer Res Treat. 2010 Nov;124(2):475-9. doi: 10.1007/s10549-010-0858-3. Epub 2010 Mar 27. Breast Cancer Res Treat. 2010. PMID: 20349127

4

Prognostic factors in primary gastric non-Hodgkin's lymphoma--a single-center retrospective analysis of 103 cases from China.

Zhang J, Hu X, Liu X, Wu X, Sun S, Zhang Q, Zhao X, Ren H, Hong X. Zhang J, et al. Among authors: zhao x. Hepatogastroenterology. 2010 Jul-Aug;57(101):989-96. Hepatogastroenterology. 2010. PMID: 21033265

5

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.

Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang J, Wang B, Wang Z, Hu X. Zhao X, et al. BMC Cancer. 2011 Sep 22;11:403. doi: 10.1186/1471-2407-11-403. BMC Cancer. 2011. PMID: 21936956 Free PMC article. Clinical Trial.

6

Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?

Zhang J, Gu SY, Gan Y, Wang ZH, Wang BY, Guo HY, Wang JL, Wang LP, Zhao XM, Hu XC. Zhang J, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):103-13. doi: 10.1007/s00280-012-1983-y. Epub 2012 Oct 2. Cancer Chemother Pharmacol. 2013. PMID: 23053266 Clinical Trial.

7

A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.

Xing K, Zhou X, Zhao X, Sun S, Luo Z, Wang H, Yu H, Wang J, Chang J, Wu X, Hu A. Xing K, et al. Among authors: zhao x. Med Oncol. 2014 Jul;31(7):36. doi: 10.1007/s12032-014-0036-2. Epub 2014 Jun 8. Med Oncol. 2014. PMID: 24908064

8

Decreased expression of RPS15A suppresses proliferation of lung cancer cells.

Zhao X, Shen L, Feng Y, Yu H, Wu X, Chang J, Shen X, Qiao J, Wang J. Zhao X, et al. Tumour Biol. 2015 Sep;36(9):6733-40. doi: 10.1007/s13277-015-3371-9. Epub 2015 Apr 3. Tumour Biol. 2015. PMID: 25833696

9

PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.

Zhao XM, Pan SY, Huang QL, Lu YN, Wu XH, Chang JH, Liu ZB, Cai XW, Liu Q, Wang JL, Fu XL. Zhao XM, et al. Oncotarget. 2016 Aug 2;7(31):49384-49396. doi: 10.18632/oncotarget.9891. Oncotarget. 2016. PMID: 27283902 Free PMC article.

10

PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes.

Zhao X, Wu X, Yu W, Cai X, Liu Q, Fu X, Liu Z, Hu D, Pan S, Huang Q. Zhao X, et al. Mol Med Rep. 2016 Dec;14(6):5369-5376. doi: 10.3892/mmr.2016.5869. Epub 2016 Oct 20. Mol Med Rep. 2016. PMID: 27779712

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51,273 results

Search Page

Filters